Activated PEGs for Amine PEGylation

JenKemPEGSynthesisJenKem Technology provides high quality polyethylene glycol derivatives for Amine PEGylation with high purity and low polydispersity.

JenKem Technology manufactures numerous PEGs with NHS and Carboxyl functionality for amine PEGylation:

PEG NHS Esters with stable linker: MPEG-SCM, MPEG-SPA, MPEG-SBA, MPEG-SHA, MPEG-SGA, MPEG-SSA, Y-PEG-NHS, MPEG2-LYS-PEG-NHS, GLUC-PEG-NHS, GALA-PEG-NHS

PEG products with carbonate linker: MPEG-SC, MPEG-NPC

Degradable PEGs with cleavable NHS ester linker: MPEG-SS and MPEG-SG

PEG Carboxyl – Y-PEG-COOH, MPEG-CM, MPEG-PA, MPEG5-PA, MPEG6-PA, MPEG-BA, MPEG-HA – more stable than NHS PEGs.

Structurally, JenKem Technology offers amine reactive linear PEGs, Y-shape PEGs, U-shape PEGs, multiarm PEGs, and monodisperse PEGs. The sterically bulky structure of JenKem Technology’s proprietary Y-shape branched PEG derivatives, consisting of two linear methoxy PEG chains attached to a central core with an active NHS group, may help to reduce the number of attachment sites to a protein molecule.

Amine PEGylation products with molecular weights, branching, and functional groups not listed in our online catalog may be available by custom synthesis. Please inquire at tech@jenkemusa.com about pricing and availability of custom activated PEGs for amine PEGylation. For global distribution, please visit link. To order directly from JenKem Technology:

ORDER ONLINE
Y-shaped  NHS PEGs with Stable Linker
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
Y-PEG-NHS ≥ 95% Y-shape PEG NHS is reactive towards the amino group of lysine(s) on proteins or other biologics. Amine PEGylation with Y-shape PEG NHS can be completed in less than 1hr at pH 7-8. JenKem proprietary Y-shape PEGs are more selective, due to their sterically bulky structure and have been employed in PEGylation of nanoparticles, Cp40, DNA aptamer (SOMAmers), G-CSF, Gentamicin, IFN-α2a, IFN-α2b, LIF receptor antagonist (LA), L-RNA (Spiegelmers), rhGH, and TNF-α, among others. [4, 25-29]
U-shaped Branched NHS PEGs with Stable Linker
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
MPEG2 LYS NHS Ester
≥ 95% MPEG2-LYS-NHS Ester is reactive towards the amino group of lysine(s), such as amines present on the active ingredients of peginterferon alpha-2a, Macugen® PEG-aptamer, Omontys®, or Pegasys®. [36]
Linear Methoxy NHS PEGs with Stable Linker
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
M-PEG-SCM ≥ 95% Methoxy PEG Succinimidyl Carboxymethyl Ester reacts with the amine group of lysine(s) at room temperature in less than 1hr at pH 7-8. Shorter hydrolysis half life of M-PEG-SCM ensures maximum selectivity towards most sterically available amine groups. [6-8]
M-PEG-SPA ≥ 95% Methoxy PEG Succinimidyl Propionate (M-SPA) reacts with the amino group of lysine(s) on proteins or other biologics, such as the active ingredients of  Somavert®, PEG-HGH antagonist, Pegvisomant, Peg growth hormone B2036 [13], pegylated granulocyte colony stimulating factor  MAXY-G34 ( PEG-CSF MAXY-G34)  [14], or Puricase PEG-uricase, Pegloticase, or Krystexxya® [33, 34] and related biosimilars. M-SPA has a longer hydrolysis half-life compared with M-PEG-SCM [12].
M-PEG-SBA ≥ 95% Methoxy PEG Succinimidyl Butanoate reacts with the amine group of lysine(s) such as the lysines on active ingredients of  Mircera®, or Peg-epo biosimilars, at room temperature at pH 7-8. Methoxy PEG Succinimidyl Butanoate has a longer hydrolysis half-life compared with M-PEG-SCM.
M-PEG-SHA ≥ 95% Methoxy PEG Succinimidyl Hexanoate reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Hexanoate has a longer hydrolysis half-life compared with M-PEG-SCM and M-PEG-SBA. [9, 31, 32]
M-PEG-SSA ≥ 95% Methoxy PEG Succinimidyl Succinamide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Succinamide has a longer hydrolysis half-life compared with M-PEG-SCM.[10]
M-PEG-SGA ≥ 90% Methoxy PEG Succinimidyl Glutaramide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Glutaramide has a longer hydrolysis half-life compared with M-PEG-SCM. [11]
Linear NHS PEGs with Cleavable Linker
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
M-PEG-SS ≥ 95% Methoxy PEG Succinimidyl Succinate is a degradable PEG linker reacting with the amino group of lysine(s) on proteins or other biologics, such as the active ingredients of Adagen®, Pegademase, PEG aspargase, PEG-L-asparaginase, or PEG-adenosine deaminase, and related biosimilars, at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.[1,2]
M-PEG-SG ≥ 95% Methoxy PEG Succinimidyl Glutarate is a degradable PEG linker that reacts with the amino group of lysine(s) on proteins or other biologics at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.
Linear Carbonate PEGs
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
M-PEG-SC ≥ 95% Methoxy PEG Succinimidyl Carbonate reacts with the amino group of lysine(s) on proteins or other biologics, such as the lysines present on proteins for Peg-intron, PEG-IFN, Interferon alpha 2b, Pegintron®, Redipen, or Sylatron, and related biosimilars.  Methoxy PEG Succinimidyl Carbonate has a longer hydrolysis half-life compared with M-PEG-SCM.[3, 35].
M-PEG-NPC ≥ 90% Methoxy PEG Nitrophenyl Carbonate is reactive towards the the amino group of lysine(s) on proteins or other biologics, with a longer hydrolysis half-life compared with M-PEG-SCM.
Linear Monosaccharide NHS PEGs
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
GALA-PEG-NHS ≥ 90% Galactose PEG NHS reacts with amino group of lysine(s) at room temperature in under 1hr, at pH 7-8. The presence of the galactose monosaccharide increases significantly the selectivity of the PEGylation reaction. [5]
GLUC-PEG-NHS ≥ 90% Glucose PEG NHS reacts with amine group of lysine(s) at room temperature in less than 1hr, at pH 7-8. The presence of the monosaccharide sugar group (Glucose) increases significantly the selectivity of the PEGylation reaction. [5, 30]
Y-shaped Branched PEG Carboxyl
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
Y-PEG-COOH ≥ 95% Y-shape PEG Carboxyl from JenKem Technology is reactive towards the amino group of lysine(s) at pH 7-8.
Linear Carboxyl PEGs
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
M-PEG-CM ≥ 95% Methoxy PEG Acetic Acid (M-COOH or M-CM) is an amine reactive reagent. Methoxy PEG Carboxyl is more stable than M-PEG-SCM.[15-17]
M-PEG5-PAM-PEG6-PA ≥ 95% Monodisperse Methoxy PEG Propionic Acid is more stable than M-PEG-SCM. JenKem Technology’s monodisperse discrete PEG Propionic Acid products are produced via very reproducible chemical reactions and lack the polydispersity of traditional PEG polymers. Rective towards the amino group of lysine(s) on proteins or other biologics. [18]
M-PEG-PA ≥ 90% Methoxy PEG Propionic Acid (M-PA, or MPEG Propanoic Acid) is more stable than M-PEG-SPA.
M-PEG-BA ≥ 90% Methoxy PEG Butanoic Acid (M-BA) is more stable than M-PEG-SBA.
M-PEG-HA ≥ 95% Methoxy PEG Hexanoic Acid is more stable than M-PEG-SHA.
Linear Homobifunctional PEGs for Amine PEGylation
PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
SCM-PEG-SCM ≥ 95% SCM PEG SCM (or NHS-PEG-NHS) Amino reactive PEG diNHS ester crosslinker for the amino group of lysine(s) on proteins or other biologics [23].
COOH-PEG-COOH ≥ 95% Carboxyl PEG Carboxyl (CM-PEG-CM, or Acetic Acid PEG Acetic Acid). Amino reactive PEG crosslinker. [19-22]
Monodisperse COOH-PEG-COOH ≥ 90% Monodisperse Carboxyl PEG Carboxyl (Discrete CM-PEG-CM, discrete Acetic Acid PEG Acetic Acid, or discrete PEG di-acetic acid). Amino reactive PEG crosslinker.
Monodisperse PA-PEG-PA ≥ 90% Monodisperse Propionic Acid PEG Propionic Acid (Discrete PA-PEG-PA, discrete PEG di-propionic acid). Amino reactive PEG crosslinker.
Linear Heterobifunctional PEGs Functionalized with Carboxyl or NHS
Heterobifunctional Carboxyl PEGs and NHS PEGs
Multiarm Homofunctional PEGs Functionalized with Carboxyl or NHS
Multiarm Homofunctional PEGs
Multiarm Heterobifunctional PEGs Functionalized with Carboxyl or NHS
Multiarm Heterobifunctional PEGs

References:

1. Mastorakos, P., et al., Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain. Small, 2015. doi:10.1002/smll.201502554.

2. Jain, S., et al., Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity, RSC Adv., 2014, 4, 29193-29201.

3. Wan, X., et al., Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins, Process Biochemistry, 2017, 52:183-91.

4. Guo, L., et al., Application Instructions for Y-NHS-40K for Amine PEGylation, link.

5. He, H., et al., Bolstering cholesteryl ester hydrolysis in liver: A hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis, Biomaterials, 2017, 130:1-3.

6. Liu, C., et al., iRGD-mediated core-shell nanoparticles loading carmustine and O6-benzylguanine for glioma therapy, Journal of Drug Targeting, 2017, 25(3):235-46.

7. Gao, W., et al., Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer, International Journal of Nanomedicine, 2017, 12:1047.

8. Yang, C., et al., Effects of PEGylation on biomimetic synthesis of magnetoferritin nanoparticles, Journal of Nanoparticle Research, 2017, 19(3):101.

9. Mesken, J., et al., Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides–Cellular uptake and enhanced gene delivery, International journal of pharmaceutics, 2017, 522(1):198-209.

10. Li, C., et al., Real-Time Monitoring Surface Chemistry-Dependent In Vivo Behaviors of Protein Nanocages via Encapsulating an NIR-II Ag2S Quantum Dot, ACS Nano, 2015, 9 (12), 12255-12263.

11. Suarez, et l., Intramyocardial injection of hydrogel with high interstitial spread does not impact action potential propagation, Acta Biomaterialia, 2015, Volume 26, Pages 13-22.

12. Pfister, D., et al., Integrated process for high conversion and high yield protein PEGylation, Biotechnol. Bioeng., 2016, doi:10.1002/bit.25932.

13. Goffin V, et al., Pegvisomant Pfizer/Sensus. Curr Opin Investig Drugs. 2004;5:463–468.

14. https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71718

15. Li, Y., et al., A graphene quantum dot (GQD) nanosystem with redox-triggered cleavable PEG shell facilitating selective activation of the photosensitiser for photodynamic therapy, RSC Adv., 2016, 6, 6516-6522.

16. Jones, S.K, et al., Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance, Biomacromolecules, 2016, 17 (1), 76-87.

17. Chaudhary, R., et al., Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents. Journal of Nanobiotechnology, 2016, 14(1):1-7.

18. Zhang, C., Impact of Large Aggregated Uricases and PEG Diol on Accelerated Blood Clearance of PEGylated Canine Uricase, PLoS One, 2012, 7(6): e39659.

19. Lorenzo, M. M., et al., Homodimeric Protein–Polymer Conjugates via the Tetrazine–trans-Cyclooctene Ligation, Macromolecules, 2015, DOI: 10.1021/acs.macromol.5b02323.

20. Xue, Y., et al., Quantifying thiol–gold interactions towards the efficient strength control, Nature communications, 2014, 5.

21. Xu, P., et al., Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis. Biomaterials, 2014. 35(26): p. 7574-7587.

22. Gajbhiye, V., et al., Drug-loaded nanoparticles induce gene expression in human pluripotent stem cell derivatives. Nanoscale, 2014. 6(1): p. 521-31.

23. Walker, J.M., et al., Magnetically Triggered Radical-Generating Fe3O4 Nanoparticles for Biopolymer Restructuring: Application to the Extracellular Matrix, Chem. Mater., 2015, 27 (24), pp 8448–8456.

24. Duncan, R., et al., Polymer therapeutics—polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities, Journal of drug targeting, 2006, 14(6), 337-341.

25. Masao, H., et al., Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys, Nucleic Acid Therapeutics, 2015, doi:10.1089/nat.2015.0567.

26. Winship, A.L., Interleukin-11 alters placentation and causes preeclampsia features in mice, Proc Natl Acad Sci U S A., 2015, 112(52):15928-33.

27. Risitano, A.M., et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood Mar, 2014, 123 (13) 2094-2101.

28. Roccaro, Aldo M. et al., SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy, Cell Reports , 9 (1), 2014.p: 118 – 128.

29. Stefan, N., et al., Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting, Bioconjugate chemistry, 2014, 25.12: 2144-2156.

30. Drappier, C., pH-Responsive Surface Shielding By Electrostatic Adsorption of PEG Segments With Anionic Chain End, Universite Bordeaux 2013.

31. Look, L., et al., Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery, Molecular Pharmaceutics, 2015, 12 (9), 3202-3213.

32. Fahrlander E., et al., PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent, Nanotechnology, 2015 Mar 19;26(14):145103.

33. Hershfield, M.S., Set al. Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout, PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhauser Basel, 2009:217-227.

34. Ma, G., PEGylated drugs: Concept, Design and Application, Science Press, 2016:314

35. Fahrländer E., et al., PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent, Nanotechnology, 2015; 26(14):145103.

36.  https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021756s006,s007lbl.pdf

Founded in 2001 by recognized experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to on-site manufacturing from ethylene oxide, enabling facile traceability for GMP regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.

Continue Reading